Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients

NCT ID NCT07713524

Completed Knowledge-focused Sponsor: Cairo University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study follows 112 critically ill patients with pre-existing kidney disease who receive one or two doses of contrast dye for imaging. Researchers track kidney function, including acute injury and long-term decline, over six months. The goal is to understand how repeated contrast exposure impacts kidney outcomes in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iodinated contrast dye
What this could lead to: If it succeeds, this could help doctors better weigh the risks of using contrast dye in patients with weak kidneys, potentially preventing further kidney damage.
What could go wrong: This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASES

Contacts and locations

Show contact details

Locations

Faculty of medicine

Cairo, KasrAlainy, 11562, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.